Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors
Helen T. Chifotides, Lucia Masárová, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo, Srđan Verstovšek
Abstract
Key Points IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with IDH1/2-mutated post–MPN AML. Complete remission was achieved in 3/7 patients (1 attaining MRD–) with new IDH1/2-mutated post–MPN AML treated with IDH1/2-i combinations.
Topics & Concepts
IDH1Myeloproliferative neoplasmInternal medicineMedicineIsocitrate dehydrogenaseOncologyCancer researchMutationBiologyGeneticsEnzymeGeneBone marrowMyelofibrosisBiochemistryMyeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia Treatments